Latest news with #Atorvastatin
Health Line
01-07-2025
- Health
- Health Line
What's the Connection Between Statins and Dementia?
There are conflicting research findings as to whether the use of statins can protect from dementia or increase the risk of dementia. While some older research has pointed to the possibility of a correlation, more recent studies showed that this drug class may lower your risk for dementia, including Alzheimer's disease. Statins are a type of medication taken to lower cholesterol levels in the blood. They prevent an enzyme called hydroxymethylglutaryl-CoA reductase (HMG-CoA reductase), which is involved in the production of cholesterol in the liver. Benefits of statins Benefits include lowering LDL ('bad') cholesterol levels, reducing the risk of heart disease, and preventing plaque buildup in your arteries. These medications include atorvastatin (Lipitor) and rosuvastatin (Crestor), among others. In 2012, the Food and Drug Administration issued a warning that statin use could rarely cause memory loss or confusion. The FDA later updated the findings that this cognitive decline was not significant. A growing body of research suggests statins may have a protective effect against dementia. A review of 31 studies published in 2018 supports the idea that statins can help prevent the risk of dementia. The researchers found that taking statins for 1 year decreased dementia risk by about 20%, while an average daily 5-milligram (mg) dose was associated with an 11% decrease in dementia risk. The researchers noted that because high cholesterol is a risk factor for dementia, lowering it could have positive effects on the brain. According to a 2020 review, statins may help short- and long-term delay of dementia progression in people over 65 years old with the condition, although the researchers noted that their findings were insufficient to make a definitive statement. Studies in 2021 and 2023 also pointed in the direction of statins having a protective effect against dementia, though the results were not conclusive. Research discrepancies Researchers in a 2022 study pointed out that discrepancies among studies is possibly related to smaller sample sizes and biases in the research methods, as well as wide ranges in the ages of participants, and co-existing conditions. Additionally, these researchers pointed out that different types of statins have different cognitive effects. Most scientists and medical professionals agree that more research is needed on the cognitive effects of statins, and there are studies in progress. If you have high cholesterol, it's important to get advice from a medical professional. High cholesterol is a risk factor for diseases that can affect your independence and life span, such as: heart disease dementia stroke heart attack While some people can experience improvement with lifestyle modifications, many who have high cholesterol need to take cholesterol-lowering medication. You and your doctor can discuss a plan that's individualized for you.
&w=3840&q=100)
Business Standard
23-05-2025
- Business
- Business Standard
Alembic Pharma receives USFDA approval for generic hypertension drug
Alembic Pharmaceuticals on Friday said it has received final approval from the US health regulator for its generic version of amlodipine and atorvastatin tablets, used to treat high blood pressure. The final approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Amlodipine and Atorvastatin tablets of strengths 2.5 mg/10 mg, 2.5 mg/20 mg, 2.5 mg/40 mg, 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 5 mg/80 mg, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg, the company said in a statement. These are therapeutically equivalent to the reference-listed drug product, Caduet tablets of corresponding strengths of Pharmacia and Upjohn Co LLC, it added. Alembic said it has a cumulative total of 223 ANDA approvals (199 final approvals and 24 tentative approvals) from the USFDA. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard
23-05-2025
- Business
- Business Standard
Alembic Pharma receives USFDA nod for Amlodipine and Atorvastatin Tablets
Alembic Pharmaceuticals announced that it has received final approval from the U.S. Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Amlodipine and Atorvastatin Tablets USP. Amlodipine and Atorvastatin tablets are a combination medication used to treat high blood pressure (hypertension) and high cholesterol (hyperlipidemia). The approved product is therapeutically equivalent to the reference listed drug, Caduet Tablets, marketed by Pharmacia and Upjohn Co. LLC. The company now has a cumulative total of 223 ANDA approvals from the USFDA, including 199 final approvals and 24 tentative approvals. Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA. The companys consolidated net profit declined 12% to Rs 156.89 crore despite a 16.7% jump in net sales to Rs 1,769.64 crore in Q4 FY25 over Q4 FY24. The counter shed 0.13% to Rs 971.25 on the BSE.
Time of India
23-05-2025
- Business
- Time of India
Alembic Pharma gets USFDA nod for generic high blood pressure treatment drug
Alembic Pharmaceuticals on Friday said it has received final approval from the US health regulator for its generic version of amlodipine and atorvastatin tablets, used to treat high blood pressure. The final approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Amlodipine and Atorvastatin tablets of strengths 2.5 mg/10 mg, 2.5 mg/20 mg, 2.5 mg/40 mg, 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 5 mg/80 mg, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg, the company said in a statement. These are therapeutically equivalent to the reference-listed drug product, Caduet tablets of corresponding strengths of Pharmacia and Upjohn Co LLC, it added. Alembic said it has a cumulative total of 223 ANDA approvals (199 final approvals and 24 tentative approvals) from the USFDA.
Irish Independent
15-05-2025
- Business
- Irish Independent
Irish exports reached record level in March, due to threat of Trump tariffs
Exports to America increased the most, up by €20.3bn last month alone, to reach a total of €25.4bn. This is an increase of almost 395pc. The stockpiling is most obvious in the pharma sector, which is operating under the threat of a tariff of up to 25pc. According to trade figures released by the Central Statistics Office, the exports of medical and pharma products rose by €16.7bn, or 243pc, to €23.6bn in March. The exports would include the active pharmaceutical ingredient (API) in Mounjaro, the weight-loss drug produced by Eli Lilly, one of the world's leading pharma companies which employs over 3,500 people in Ireland across three sites. Medical and pharma represents almost two-thirds of total Irish exports. In the first quarter of 2025, amid much stockpiling in advance of Mr Trump's threatened tariff regime, Irish exports in this sector increased by 154pc to €55.9bn worth of goods. The figure for the first quarter of last year was €22bn. Of the goods exported from Ireland to America, 94pc were defined as chemicals and related products, which would include medical and pharmaceutical products. Among the other prominent exports in this category would be Sildenafil and Atorvastatin, the APIs that Pfizer produces and which are marketed as Viagra and Lipitor. Kate English, Chief Economist at Deloitte Ireland, said the March figures confirm the trend of exports to the US rising considerably in response to the threat of tariffs. 'There is a clear indication of stockpiling of medical and pharmaceutical products, with exports to the US increasing by 833pc in March 2025 compared to March last year,' she said. "With such a notable rise, this is likely to positively impact Q1 GDP data. However, will this level of export trade, driven by stockpiling, hold in the second quarter? If it doesn't, we are likely to see more noise in Q2 GDP data.' 'This will make interpreting some economic data in the first half of the year quite difficult, meaning we need to continue to monitor other frequent data points, such as consumer sentiment and savings ratios." Further evidence of the sheer volume of Irish pharma exports to America in the first quarter emerged in figures from the Census Bureau in America. Released this week they showed that the US imported a record $53bn of medical and pharma products in March, up 160pc from the same month last year, and almost double the quantity of February. Ireland accounted for $28bn of the imports in March, according to the US figures, up from $5.5bn in the same month in 2024. Robert Purdue, Head of Dealing (Ireland) at global financial services firm Ebury, said: "Irish exports went through the roof in March as businesses rushed to sell their goods, particularly chemicals and pharmaceuticals, to the US. "The sheer scale of this growth - almost doubling compared to March 2024 - demonstrates the impressive resilience and capability of Ireland's exporting sector. However, more worryingly, it suggests that Ireland is unlikely to escape the firing line of US President Trump's tariff war. "With the President targeting countries with trading surpluses with the US, and with his recent criticisms of the EU, Irish businesses will be hoping that the UK trade deal announced last week will pave the way for a fair and balanced trading arrangement between Ireland and the US.' The US administration is currently doing a Section 232 national security investigation into both drugs and semiconductors, which it is widely feared will lead to the announcement of sectoral-specific tariffs in addition to the general 10pc levy imposed by Mr Trump in April.
